Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Automated Immunoassay for Testosterone Evaluated

By LabMedica International staff writers
Posted on 21 Feb 2011
A new electrochemiluminescence testosterone immunoassay has been evaluated and compared with existing methods.

The competitive immunoassay uses high affinity sheep monoclonal testosterone-specific antibody, which is complexed with the serum samples, and after processing the chemiluminescent emissions are measured by a photomultiplier.

Scientists at the University Medical Center Göttingen, (German), collaborated with others medical centers to evaluate the second-generation electrochemiluminescence assay and compare it to a validated assay. The scientists investigated the within-run precision, total precision, and method comparisons to the former immunoassay and the liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. They were also interested in establishing reference intervals for adults and children. Special attention was paid to females with acute renal failure.

The within-run precision and total precision were determined using five different and site-specific human serum pools and two quality control samples. The within-run imprecision ranged from 12.8 μg/L, (0.9%) to 0.23 μg/L (5.2%), and total imprecision ranged from 12.7 μg/L (2.2%) to 0.22 μg/L (8.5%). The recovery according to quality control sample target values was 2.51 μg/L (95.4%) at one center, and 6.30 μg/L (103.6%) at another.

The new Elecsys Testo II assay (Roche Diagnostics GmbH, Mannheim, Germany) was compared against the former Roche Elecsys Testo assay and to a validated LC-MS/MS assay. Precision was improved especially at concentrations below 2.0 μg/L when compared to the former Elecsys Testo assay. The measuring range of 0.12 μg/L to 15.0 μg/L fulfils clinical needs. The new Elecsys Testo II assay demonstrated superior agreement in comparison to the validated LC-MS/MS method indicating an improved specificity.

Surprisingly, some high testosterone concentrations were found in samples from female patients, as confirmed by LC-MS/MS, as these individuals were suffering from polycystic ovary (PCO) syndrome or even androgen-producing tumors. The authors noted that overestimated values, especially with the former Elecsys immunoassay as compared to LC-MS/MS, were found to be from patients suffering from end-stage renal disease undergoing hemodialysis. The study was published in February 2011, in Clinical Biochemistry.

Related Links:
University Medical Center Göttingen
Roche Diagnostics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Biological Indicator Vials
BI-O.K.
New
Vaginitis Test
Allplex Vaginitis Screening Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.